Search results for: Market Access
Filter search results
A Final MVAC Blueprint—and the Start of an R&D Revolution?
6 February 2020
TB kills 1.6m people annually – the world’s deadliest infectious disease. The Market-Driven, Value-Based Advance Commitment (MVAC), creates and guarantees a market for better TB treatment. The final “blueprint” has…
The Economics of Innovation in Times of Pandemic: How to Incentivise the Development, Supply, and Continuous Improvement of Innovative Solutions to Fight COVID-19?
22 May 2020
…and purchase contracts were directed at the first to market. Investment in potentially better technologies offering more health gain and economic benefit would be abandoned and never reach the market….
The Dynamics of Drug Shortages
9 January 2024
…the most shortages are generic and biosimilar manufacturers. The concentration of shortage incidents in the off-patent market may be due to these being commercially unattractive markets with low-profit margins and…
What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
19 November 2024
…topic). In recognition of this challenge, and as part of the Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) 2024, DHSC is updating the Commercial Framework to be more explicit…
Drug shortages are on the rise – but what is their impact?
16 September 2024
…AAM, 2022. Report: 2022 U.S. Generic and Biosimilar Medicines Savings Report | Association for Accessible Medicines. [online] Available at: https://accessiblemeds.org/resources/reports/2022-savings-report [Accessed 10 Sep. 2024]. ASPE, 2023. ASPE Report to Congress: Impact of…
The World Needs Better Drugs for TB. The Center for Global Development and OHE Have a Proposal and We Need your Feedback
5 March 2019
…and profitable market for better TB treatment. Yet despite the clear health need and potential return, private sector actors have mostly shied away from this market. A major reason for this…
The Inflation Reduction Act: Price negotiation underway for the first 10 drugs
29 November 2023
…pharmaceutical market is the largest in the world. Coupled with high healthcare expenditures, the US also enjoys the broadest and fastest access to medicines globally. Among the biggest questions that…
The Road to Sustainability in the UK and German Biotechnology Industries
1 August 2000
…ranked by market capitalisation, are yet earning profits. The risks and costs of bringing new products to market are large. On average it takes 11 years and hundreds of millions…
The Impact of Biosimilars on Markets
24 May 2010
The availability of biosimilars — ‘copies’ of biologics — is very recent and limited so far to only a few products. Projecting the impact on markets of the appearance of…